Stock Movers: Carmax, Darden Restaurants, Circle
On this episode of Stock Movers: - CarMax (KMX) shares rise after comparable sales and earnings per share for the first quarter that beat consensus estimates. - Darden (DRI) share rise after the company reported comparable sales growth for the fourth quarter that topped the average analyst estimate. - Circle (CRCL) shares rise after the US Senate passed stablecoin legislation setting up regulatory rules for crypto currencies pegged to the dollar.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Eli Lilly (NYSE:LLY) Faces $7 Billion Lawsuit While Partnering With Innovative Biotech
Eli Lilly has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent developments, signaling strengthened research capabilities in precision immunotherapies and potentially bolstering investor confidence. Additionally, the company's legal entanglement with the lawsuit concerning Actos, following a class certification affirmation, highlights ongoing challenges in the pharmaceutical sector. The company's ongoing talks to acquire Verve Therapeutics also show its commitment to growing its gene-editing capabilities. These events have added weight to the broader market's trends. We've identified 2 warning signs for Eli Lilly (1 can't be ignored) that you should be aware of. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Recent developments at Eli Lilly, such as the RyboDyn Inc. collaboration, have potential implications for its strategic growth, particularly in precision immunotherapies. This aligns with the company's narrative of expanding capabilities in oncology and immunology, indicating possible enhancements in revenue and earnings forecasts over the long term. Additionally, as Eli Lilly progresses with Phase III trials, including those for orforglipron, the anticipated product approvals could bolster revenue avenues by tapping into high-demand markets like diabetes and obesity treatments. Over the past five years, Eli Lilly's total shareholder return was a very large 430.14%, demonstrating substantial long-term growth despite recent underperformance against the US Pharmaceuticals industry, which saw a 8.9% drop over the past year. This impressive five-year return provides context to the company's current position, underscoring a history of robust shareholder value creation. Given the ongoing acquisition talks with Verve Therapeutics and Eli Lilly's significant investment in both manufacturing and R&D, the outlook for future revenue and earnings remains optimistic. However, potential regulatory hurdles and pricing pressures, particularly in the U.S. market, highlight possible challenges. The shares, with a current price of US$775.12, are 21.0% below the analyst consensus target of US$981.63. This discount suggests room for growth, should the company meet or exceed the analyst expectations on revenue and earnings. Learn about Eli Lilly's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
Stellantis Evaluates Maserati's Future, Including Potential Sale -- Reuters
Stellantis (STLA, Financials) is weighing a possible sale of its luxury brand Maserati as part of a broader strategic review, according to a Reuters report citing two unnamed sources familiar with the matter. Warning! GuruFocus has detected 11 Warning Signs with STLA. The discussions reportedly began before newly appointed CEO Antonio Filosa officially takes the helm. Maserati's future is under review as Stellantis navigates a shrinking U.S. market, Chinese competition, and steep tariffs imposed by President Donald Trump on foreign-made cars and parts. Despite the internal review, a Stellantis spokesperson told Reuters that Maserati is not for sale. McKinsey declined to comment. Maserati's sales fell by over 50% last year to 11,300 units, with no new models currently scheduled for launch. A new business plan is expected once Filosa begins his tenure. Stellantis' board remains split on the brand's futuresome directors reportedly view Maserati as a reputational asset, while others believe it lacks viability for a sustainable relaunch. Analysts say streamlining Stellantis' 14-brand portfolio could improve profit margins. The company's shares have lost roughly two-thirds of their value since March 2024. Chinese automakers such as Chery could emerge as potential buyers, echoing earlier moves like Geely's acquisition of Volvo or SAIC's purchase of MG. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
35 minutes ago
- New York Times
Senator Ron Johnson Resists G.O.P. Megabill, Warning It Will Swell Debt
President Trump had some blunt advice for Senator Ron Johnson, the Wisconsin Republican who had been publicly excoriating his signature tax and spending bill as a deficit-driving debacle, at a tense White House meeting this month. Be nice, the president told the businessman-turned-ultraconservative politician. Mr. Johnson immediately toned down his vocal drumbeat of criticism against the plan. But he still looms as a significant obstacle to the sweeping domestic policy bill that Senate Republicans hope to push through next week. Not only does he declare himself adamantly opposed to the current version, he is simultaneously undercutting the party's message that the legislation will not pile on to federal deficits. He is, however, trying to be nicer about it. 'I'm a pretty flexible, reasonable guy,' the sometimes disputatious, three-term Republican referred to on Capitol Hill as 'RonJohn' told reporters on Wednesday, drawing scoffs of disbelief. 'I am!' Mr. Johnson put his accounting background to work in a dense, 30-page report he released this week that rejects claims by the administration and Republican leaders that the combination of continued tax cuts, spending reductions in the range of $1.5 trillion over 10 years and new policies will spur growth to offset lost tax revenue. Under almost any scenario, his report says, deficits will continue to soar above $2 trillion per year, for a cumulative $20 trillion or more over the 10-year life span of the bill. That is in line with — though substantially more favorable than — estimates by the nonpartisan Congressional Budget Office and fiscal research groups that have found that the costs of the bill would swamp any growth it could create. Want all of The Times? Subscribe.
